Previous Close | 0.1651 |
Open | 0.1651 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.1651 - 0.1651 |
52 Week Range | 0.1620 - 1.4800 |
Volume | |
Avg. Volume | 1,050 |
Market Cap | 6.425M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0680 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AGTX
Niche Companies in Technology, Technology, FinTech, Consumer Products, Healthcare, Media, and more in attendanceMIAMI, Feb. 15, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 25th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management team
Phoenix, Arizona--(Newsfile Corp. - January 4, 2022) - The Stock Day Podcast welcomed AGENTIX (OTC Pink: AGTX) ("the Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly.Jolly began the interview
New York, New York--(Newsfile Corp. - December 21, 2021) - AGENTIX Corporation (OTC Pink: AGTX), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases, announced today it has entered into an amendment to a Patent and Know-How License Agreement between the parties, dated October 22, 2021, a worldwide exclusive license and services agreement with Research Triangle Institute, dba RTI International ("RTI"), a nonprofi